Adam Vorstein

What Adam Vorstein has said on podcasts

6 statements

1. on In-vivo CAR-T developmentNegativeOct 8, 2026· The Readout Loud

   In-vivo CAR-T development has crowded out off-the-shelf CAR-T companies such as Caribou.

   “they've kind of just boxed out the off-the-shelf companies like Caribou”

   Listen at 7:34

   Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers
2. on Widely owned biotech stocksNegativeOct 8, 2026· The Readout Loud

   Widely owned biotech stocks have underperformed, particularly since August.

   “many of the biotech stocks that are most commonly owned by both like the specialist funds and even retail investors. You call those the crowded longs, like lots and lots of people own these stocks. They are underperforming, particularly since August.”

   Listen at 10:38

   Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers
3. on Frequently shorted biotech stocksPositiveOct 8, 2026· The Readout Loud

   Frequently shorted biotech stocks are outperforming.

   “stocks that are often. shorted, meaning investors are betting that the stock prices will go down. Those stocks are actually outperforming.”

   Listen at 10:59

   Open the episode · 416: NIH funding uncertainty thwarts U.S. researchers

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

• Oct 8, 2026NIH uncertainty puts America’s biomedical pipeline at riskThe Readout LoudOct 8, 2026Guest